Royal Philips has unveiled Verida, the world’s first detector-based spectral CT system fully powered by AI, marking a major breakthrough in computed tomography. The new platform integrates AI across the entire imaging chain—from acquisition to reconstruction—to reduce system noise, enhance image clarity, and significantly accelerate clinical workflows.

Philips already has more than 800 global installations of its spectral CT technology, backed by over 800 peer-reviewed publications. Its detector-based spectral CT provides multiple spectral results from a single scan, without compromising performance or scan time, and is already seamlessly integrated into clinical workflows.

The new Verida system elevates this platform by leveraging AI to deliver sharper spectral images, lower noise, and high-definition conventional scans. It enables substantial dose reductions, lowers energy consumption by up to 45%, and produces reconstructions at 145 images per second, allowing entire exams to appear in under 30 seconds—twice as fast as before. With this capacity, Verida can support up to 270 exams per day.

Clinicians say Verida’s capabilities may redefine cardiac imaging and improve diagnostic confidence across multiple specialties. Prof. Eliseo Vañó Galván, cardiovascular radiologist at Hospital Nuestra Sra. del Rosario in Madrid, noted that Verida’s precision and ease of use will allow his department to move toward routine spectral imaging for all patients, potentially reducing invasive angiograms.

Built on Philips’ Spectral Precise Image technology—combining deep learning reconstruction with its third-generation Nano-panel Precise dual-layer detector—the system is engineered for faster, more dose-efficient imaging while delivering rich spectral insights from a single scan.

“By combining our proven spectral CT technology with AI, Verida sets a new benchmark for image quality and workflow speed,” said Dan Xu, business leader for CT at Philips. “Unlike photon-counting CT, which remains early in clinical adoption, our spectral CT has been a reliable clinical workhorse for over a decade and delivers comparable or better outcomes at a significantly lower total cost of ownership.”

Philips will debut Verida at RSNA 2025, with commercial availability beginning in select markets in 2026. The launch extends Philips’ software-driven CT strategy to support earlier disease detection, reduce diagnostic variability, and improve operational efficiency across care settings.